Gan & Lee Pharmaceuticals (603087.SH) has released its 2025 annual performance forecast, anticipating a net profit attributable to owners of the parent company in the range of 1.10 billion to 1.20 billion yuan. This represents an increase of 485 million to 585 million yuan compared to the same period last year (based on legally disclosed data), translating to a year-on-year growth of 78.96% to 95.23%.
The company expects a substantial increase in net profit attributable to owners for 2025, primarily driven by revenue growth in both domestic and international markets, as well as gains from equity transfers.
In the domestic market, building upon the market coverage advantages secured through centralized drug procurement, the company has continuously deepened and expanded its market presence, achieving significant simultaneous growth in both the sales volume and revenue of its insulin preparation products.
In the international market, the company has actively advanced its global strategy, achieving notable results in expanding along the "Belt and Road" routes and in emerging markets. It has successfully gained the trust and cooperation opportunities of more international clients, leading to sales growth in several key markets.
During 2025, the company reached a consensus agreement with Guangdong Hengqin Ganliang Enterprise Management Co., Ltd. (hereinafter referred to as "Hengqin Ganliang") to transfer a total of 70% equity of its wholly-owned subsidiary, Gangan Medical Technology Jiangsu Co., Ltd. (hereinafter referred to as "Gangan Jiangsu"), to Hengqin Ganliang in two steps. In 2025, the company completed the first step of the transaction, successfully transferring 55% of the equity in Gangan Jiangsu, which increased investment income and consequently boosted the company's net profit.
Comments